Featured Posters & Presentations
Lyfgenia
Participants with sickle cell disease (SCD) and a history of stroke in lovotibeglogene autotemcel.
Authors: Jaroscak JJ.
Lyfgenia
An update on lovotibeglogene autotemcel (lovo-cel) clinical trials for sickle cell disease (SCD) and analysis of early predictors of response to lovo-cel.
Authors: Rifkin-Zenenberg S
Zynteglo
Betibeglogene autotemcel (Beti-cel) gene addition therapy results in durable hemoglobin A (HbA) production with up to 10 years of follow-up in participants with transfusion-dependent β-thalassemia.
Authors: Thompson AA.